LOS ANGELES (Reuters) – Eastbourne Capital, which owned a 12.5-percent stake in Amylin Pharmaceuticals Inc (AMLN.O: Quote, Profile, Research, Stock Buzz) as of late August, said on Monday it intends to hold discussions on ways to improve shareholder value, including the possible sale of the biotechnology company.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
